Results 131 to 140 of about 67,162 (289)
Abstract BNC210 is an investigational small molecule selective negative allosteric modulator of the alpha‐7 nicotinic acetylcholine receptor (α7 nAChR). It is an anxiolytic compound with a novel mechanism of action. In a series of Phase 1 clinical trials in healthy volunteers, psychometric test batteries showed that BNC210 did not cause attention ...
Paul Rolan +7 more
wiley +1 more source
Challenges of the allosteric regulation of hemoglobin by interaction with Cys93 of the β chain for the treatment of sickle cell disease [PDF]
Eric J. Niesor +5 more
openalex +1 more source
Abstract Asciminib is the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP) in patients with chronic myeloid leukemia. This phase 1, two‐treatment‐period, drug‐drug interaction study evaluated the effect of steady‐state asciminib on the pharmacokinetics of atorvastatin.
Matthias Hoch +9 more
wiley +1 more source
Allosteric regulation of kinase activity in living cells. [PDF]
Godbole SS, Dokholyan NV.
europepmc +1 more source
Transient Allosteric Regulation of Catalysis by Effector Switching in a Pt2L4 Cage [PDF]
Joost N. H. Reek, Zoe Ashbridge
openalex +1 more source
eLife Assessment: Allosteric regulation of kinase activity in living cells [PDF]
Volker Dötsch
openalex +1 more source
Pharmacogenomics of Major Depressive Disorder in Indigenous Amazonian Populations
Major depressive disorder is a highly prevalent psychological disorder worldwide and its main treatment is the use of Selective Serotonin Reuptake Inhibitors. However, few studies have demonstrated the relationship between the presence of genetic variants in pharmacogenes and the efficacy of these drugs, especially in populations with a unique genetic ...
Kaio Evandro Cardoso Aguiar +9 more
wiley +1 more source
Considerations for drug trials in hypertrophic cardiomyopathy
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant +17 more
wiley +1 more source

